Immunogenicity and safety of measles vaccine in ill African children.
A concurrent prospective study was conducted in Rwanda to compare the immunogenicity and safety of live, attenuated measles vaccine in ill and well children. Five hundred and eighteen children aged 8 to 19 months were selected from children attending the acute care and immunization services of two clinics. Two hundred and sixty-seven ill children and 251 well children were enrolled and examined. Serological tests were performed on blood samples obtained before and 40 days after measles immunization. Among the 208 ill children and 215 well children who were seronegative at baseline and had unequivocal follow-up serological results, seroconversion rates were 81% and 80%, respectively. Side effects were modest and were equally frequent in the two study groups (15.4% among ill children versus 15.1% among well children). These results support a change in measles immunization policy in developing countries with respect to immunization of children with acute illnesses. Such a change would make a great contribution to decreasing the enormous burden of measles in the developing world through increased immunization coverage.
D000914:Antibodies, Viral / Q000096:biosynthesis; D005260:Female; D006304:Health Status; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008297:Male; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D011446:Prospective Studies; D012432:Rwanda; D012449:Safety
D000914:Antibodies, Viral; D008458:Measles Vaccine